• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Beta Bionics Inc.

    2/3/25 6:03:40 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care
    Get the next $BBNX alert in real time by email
    S-8 1 d924783ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on January 31, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Beta Bionics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   83-5386878

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    11 Hughes

    Irvine, California 92618

      92618
    (Address of Principal Executive Offices)   (Zip Code)

    Beta Bionics, Inc. Amended and Restated 2016 Equity Incentive Plan

    Beta Bionics, Inc. 2025 Equity Incentive Plan

    Beta Bionics, Inc. 2025 Employee Stock Purchase Plan

    (Full titles of the plans)

    Sean Saint

    President and Chief Executive Officer

    Beta Bionics, Inc.

    11 Hughes

    Irvine, California 92618

    (949) 427-7785

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Carlos Ramirez

    Mark Weeks

    Charles S. Kim

    Cooley LLP

    10265 Science Center Drive

    San Diego, CA 92121

    (858) 550-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large Accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

    The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act of 1933, as amended (the “Securities Act”) and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the Commission:

     

      (a)

    The Registrant’s prospectus filed on January  31, 2025 pursuant to Rule 424(b) of the Securities Act relating to the Registration Statement on Form S-1, as amended (File No. 333-284147), initially filed with the Commission on January 6, 2025, which contains audited financial statements for the Registrant’s latest fiscal year for which such statements have been filed; and

     

      (b)

    The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A filed on January 27, 2025 (File No. 001-42491) under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.

    All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or portions thereof that are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    As permitted by Sections 102 and 145 of the Delaware General Corporation Law, the Registrant has adopted provisions in its amended and restated certificate of incorporation and amended and restated bylaws that limit or eliminate the personal liability of its directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to the Registrant or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:

     

      •  

    any breach of the director’s duty of loyalty to the Registrant or its stockholders;


      •  

    any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

     

      •  

    any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or

     

      •  

    any transaction from which the director derived an improper personal benefit.

    These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. The Registrant’s amended and restated certificate of incorporation also authorizes it to indemnify its officers, directors and other agents to the fullest extent permitted under Delaware law.

    As permitted by Section 145 of the Delaware General Corporation Law, the Registrant’s amended and restated bylaws provide that:

     

      •  

    the Registrant may indemnify its directors, officers, employees and other agents to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions;

     

      •  

    the Registrant may advance expenses to its directors, officers and employees in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and

     

      •  

    the rights provided in the Registrant’s bylaws are not exclusive.

    The Registrant’s amended and restated certificate of incorporation and its bylaws, as amended, provide for the indemnification provisions described above. The Registrant has entered into, and intends to continue to enter into, separate indemnification agreements with its directors and officers that may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements generally require the Registrant, among other things, to indemnify its officers and directors against certain liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements also generally require the Registrant to advance any expenses incurred by the directors or officers as a result of any proceeding against them as to which they could be indemnified. These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of the Registrant’s officers and directors for liabilities, including reimbursement of expenses incurred, arising under the Securities Act.

    The Registrant has purchased and currently intends to maintain insurance on behalf of each and every person who is one of its directors or officers, within the limits and subject to the terms and conditions thereof, against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.

    Item 7. Exemption from Registration Claimed.

    Not applicable.


    Item 8. Exhibits.

    The exhibits to this Registration Statement are listed below:

     

    Exhibit
    Number
      

    Description

      4.1    Amended and Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-42491, filed with the Commission on January 31, 2025).
      4.2    Amended and Restated Bylaws, as currently in effect (incorporated herein by reference to Exhibit 3.4 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-284147), filed with the Commission on January 6, 2025).
      4.3    Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-284147), filed with the Commission on January 6, 2025).
      4.4    Amended and Restated Investor Rights Agreement, dated November  8, 2024, by and among the Registrant and certain of its stockholders (incorporated herein by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-284147), filed with the Commission on January 6, 2025).
      5.1*    Opinion of Cooley LLP.
     23.1*    Consent of Independent Registered Public Accounting Firm.
     23.2*    Consent of Cooley LLP (included in Exhibit 5.1).
     24.1*    Power of Attorney (included on signature page).
     99.1    Beta Bionics, Inc. Amended and Restated 2016 Stock Incentive Plan (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-284147), filed with the Commission on January 6, 2025).
     99.2    Forms of Option Agreement, Notice of Stock Option Grant and Exercise Notice under the Beta Bionics, Inc. Amended and Restated 2016 Stock Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-284147), filed with the Commission on January 6, 2025).
     99.3*    Beta Bionics, Inc. 2025 Equity Incentive Plan.
     99.4    Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the Beta Bionics, Inc. 2025 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-284147), filed with the Commission on January 6, 2025).
     99.5    Forms of Restricted Stock Unit Grant Notice and Award Agreement under the Beta Bionics, Inc. 2025 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.6 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-284147), filed with the Commission on January 6, 2025).
     99.6    Forms of Stock Option Grant Double Trigger Grant Notice and Award Agreement under the Beta Bionics, Inc. 2025 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.7 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-284147), filed with the Commission on January 22, 2025)

     


     99.7    Forms of Restricted Stock Unit Double Trigger Grant Notice and Award Agreement under the Beta Bionics, Inc. 2025 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.8 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-284147), filed with the Commission on January 22, 2025).
     99.8*    Beta Bionics, Inc. 2025 Employee Stock Purchase Plan.
    107*    Filing Fee Disclosure and Payment Methods.

     

    *

    Filed herewith.

    Item 9. Undertakings.

     

    (a)

    The undersigned Registrant hereby undertakes:

     

      (1)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

      (i)

    To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

      (ii)

    To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

     

      (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

      (2)

    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

      (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)

    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     


    (c)

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, California, on January 31, 2025.

     

    BETA BIONICS, INC.

    By:   /s/ Sean Saint
      Sean Saint
      President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sean Saint and Stephen Feider and each of them, as his or her true and lawful attorneys-in-fact and agents, and each of them, with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

      

    Date

    /s/ Sean Saint

    Sean Saint

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

       January 31, 2025

    /s/ Stephen Feider

    Stephen Feider

      

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

       January 31, 2025

    /s/ Adam Lezack

    Adam Lezack

       Chairperson of the Board of Directors    January 31, 2025

    /s/ Sean Carney

    Sean Carney

       Director    January 31, 2025

    /s/ Dan Dearen

    Dan Dearen

       Director    January 31, 2025

    /s/ Christy Jones

    Christy Jones

       Director    January 31, 2025

    /s/ Maria Palasis, Ph.D.

    Maria Palasis, Ph.D.

       Director    January 31, 2025

     

    Get the next $BBNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BBNX

    DatePrice TargetRatingAnalyst
    2/24/2025Buy
    BofA Securities
    2/24/2025$30.00Buy
    Lake Street
    2/24/2025$25.00Buy
    Stifel
    2/24/2025$26.00Overweight
    Piper Sandler
    2/24/2025$28.00Outperform
    Leerink Partners
    2/20/2025$20.00Neutral
    Ladenburg Thalmann
    2/20/2025$20.00Neutral
    Robert W. Baird
    More analyst ratings

    $BBNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Michel Gerard J was granted 12,547 shares (SEC Form 4)

      4 - Beta Bionics, Inc. (0001674632) (Issuer)

      3/27/25 7:04:55 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Michel Gerard J

      3 - Beta Bionics, Inc. (0001674632) (Issuer)

      3/27/25 7:00:25 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Director Lezack Adam was granted 11,247 shares (SEC Form 4)

      4 - Beta Bionics, Inc. (0001674632) (Issuer)

      3/18/25 8:00:11 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care

    $BBNX
    Leadership Updates

    Live Leadership Updates

    See more
    • Beta Bionics Announces Board Appointment of Gerard Michel

      IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a

      3/27/25 4:45:06 PM ET
      $BBNX
      $DCTH
      Medical/Dental Instruments
      Health Care

    $BBNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities initiated coverage on Beta Bionics

      BofA Securities initiated coverage of Beta Bionics with a rating of Buy

      2/24/25 1:34:43 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Beta Bionics with a new price target

      Lake Street initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $30.00

      2/24/25 9:48:29 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on Beta Bionics with a new price target

      Stifel initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $25.00

      2/24/25 7:03:36 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care

    $BBNX
    Financials

    Live finance-specific insights

    See more
    • Beta Bionics to Announce First Quarter 2025 Financial Results on May 6, 2025

      IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2025 financial results after the financial markets close on Tuesday, May 6, 2025. In connection with the release, management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. You may also access the live c

      4/16/25 4:05:00 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

      IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2024 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived

      2/27/25 7:00:00 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care

    $BBNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BBNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BBNX
    SEC Filings

    See more
    • Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025

      IRVINE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2025 and raised its annual guidance for the year ending December 31, 2025. First Quarter 2025 Financial Results & Key Metrics Net sales of $17.6 million, up 36% compared to $12.9 million in the first quarter of 2024. Durable Medical Equipment (DME) channel net sales of $13.8 million, up 14% compared to $12.1 million in the first quarter of 2024.Pharmacy Benefit Plan (PBP) channel net sales of $3.8 million, up 360% compared to $0.8 million in the first quarte

      5/6/25 4:02:00 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Beta Bionics to Present at the Bank of America Securities Health Care Conference

      IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the Bank of America Securities Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at 12:35 pm Eastern Time (9:35 am Pacific Time). A live audio webcast of the presentation will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay following the event. About Beta Bionics Beta Bionics, Inc. is a commercial-stage medical device company engaged in the desig

      5/1/25 8:00:00 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Beta Bionics to Announce First Quarter 2025 Financial Results on May 6, 2025

      IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2025 financial results after the financial markets close on Tuesday, May 6, 2025. In connection with the release, management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. You may also access the live c

      4/16/25 4:05:00 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Chief Product Officer Mensinger Mike bought $566,950 worth of shares (33,350 units at $17.00), converted options into 15,107 shares, exercised 10,575 in-the-money shares at a strike of $0.02 and sold $221 worth of shares (13 units at $17.00) (SEC Form 4)

      4 - Beta Bionics, Inc. (0001674632) (Issuer)

      2/3/25 8:30:15 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Large owner Wellington Hadley Harbor Aggregator Iv, L.P. converted options into 2,901,599 shares and bought $17,000,000 worth of shares (1,000,000 units at $17.00) (SEC Form 4)

      4 - Beta Bionics, Inc. (0001674632) (Issuer)

      2/3/25 4:49:52 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Beta Bionics Inc.

      10-Q - Beta Bionics, Inc. (0001674632) (Filer)

      5/6/25 4:20:28 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Beta Bionics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Beta Bionics, Inc. (0001674632) (Filer)

      5/6/25 4:03:09 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 10-K/A filed by Beta Bionics Inc.

      10-K/A - Beta Bionics, Inc. (0001674632) (Filer)

      3/28/25 4:05:42 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care